<p>MBB Public Markets I LLC 在第一季度根据其最近向证券交易委员会提交的文件收购了 DexCom, Inc. (NASDAQ:DXCM - 免费报告) 的新股份。该公司收购了 4,154 股医疗设备公司的股票，价值约为 284,000 美元。</p>
<ul>
<li>DexCom 股票：盈利超预期和新市场准入推动看涨案例</li>
</ul>
<p>其他一些对冲基金和机构投资者最近也调整了对 DXCM 的持股。Golden State Wealth Management LLC 在第一季度将其在 DexCom 的持仓提高了 211.2%。Golden State Wealth Management LLC 目前拥有 389 股医疗设备公司的股票，价值 27,000 美元，此前在上个季度又收购了 264 股。Private Trust Co. NA 在第一季度将其在 DexCom 的持仓提高了 99.4%。Private Trust Co. NA 目前拥有 672 股医疗设备公司的股票，价值 46,000 美元，此前在上个季度又收购了 335 股。Farther Finance Advisors LLC 在第一季度将其在 DexCom 的持仓提高了 29.3%。Farther Finance Advisors LLC 目前拥有 3,100 股医疗设备公司的股票，价值 209,000 美元，此前在上个季度又收购了 702 股。Dynamic Advisor Solutions LLC 在第一季度将其在 DexCom 的持仓提高了 34.2%。Dynamic Advisor Solutions LLC 目前拥有 5,235 股医疗设备公司的股票，价值 357,000 美元，此前在上个季度又收购了 1,333 股。最后，Stonebridge Financial Group LLC 在第一季度将其在 DexCom 的持仓提高了 944.5%。Stonebridge Financial Group LLC 目前拥有 3,217 股医疗设备公司的股票，价值 220,000 美元，此前在上个季度又收购了 2,909 股。目前 97.75% 的股票由机构投资者持有。</p>
<h2>华尔街分析师观点</h2>
<p>一些股票研究分析师最近对 DXCM 股票发表了评论。Canaccord Genuity Group 在 8 月 1 日的研究报告中重申了 &#34;买入&#34; 评级，并设定了 106.00 美元的目标价。Argus 在 8 月 21 日的报告中开始覆盖 DexCom 股票。他们对该公司给予了 &#34;买入&#34; 评级和 100.00 美元的目标价。William Blair 在 7 月 31 日的报告中将 DexCom 股票评级提升至 &#34;强力买入&#34;。Mizuho 在 7 月 16 日的报告中将 DexCom 股票的目标价从 95.00 美元提高至 100.00 美元，并给予该股票 &#34;跑赢大盘&#34; 的评级。最后，摩根士丹利在 7 月 15 日的报告中将 DexCom 股票的目标价从 82.00 美元提高至 89.00 美元，并给予该股票 &#34;持平&#34; 的评级。三位分析师对该股票给予了强力买入评级，十四位给予了买入评级，五位给予了持有评级。根据 MarketBeat.com 的数据，该公司的平均评级为 &#34;适度买入&#34;，共识目标价为 99.89 美元。</p>
<ul>
<li>3 只新 ETF 正在吸引投资者的关注</li>
</ul>
<p><strong>阅读我们关于 DXCM 的最新研究报告</strong></p>
<h2>DexCom 价格表现</h2>
<p>NASDAQ:DXCM 周五开盘价为 76.00 美元。该公司的市值为 298 亿美元，市盈率为 52.78，PEG 比率为 1.59，贝塔值为 1.48。DexCom, Inc. 的一年低点为 57.52 美元，一年高点为 93.25 美元。该公司的 50 日移动平均价格为 81.01 美元，200 日移动平均价格为 78.80 美元。该公司的债务与股本比率为 0.48，流动比率为 1.52，速动比率为 1.35。</p>
<ul>
<li>关注的三只股票：期权交易者押注大幅收益</li>
</ul>
<p>DexCom (NASDAQ:DXCM - 获取免费报告) 最近于 7 月 30 日发布了季度财报。该医疗设备公司报告本季度每股收益为 0.48 美元，超出分析师共识预期的 0.45 美元，超出幅度为 0.03 美元。该公司本季度的收入为 11.6 亿美元，而分析师预期为 11.3 亿美元。DexCom 的净利润率为 13.29%，股本回报率为 30.41%。与去年同期相比，该公司的季度收入增长了 15.2%。在去年同期，该公司每股收益为 0.43 美元。DexCom 已设定其 2025 财年的每股收益指导。整体而言，股票研究分析师预计 DexCom, Inc. 今年将发布 2.03 的每股收益。</p>
<h2>DexCom 的内部交易</h2>
<p>在其他消息中，董事 Mark G. Foletta 于 8 月 15 日在一笔交易中出售了 2,750 股该股票。这些股票以平均价格 81.06 美元出售，总价值为 222,915.00 美元。出售后，该董事在公司中持有 51,121 股，价值 4,143,868.26 美元。这代表其持股减少了 5.10%。该交易已在向证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站获取。此外，董事 Kyle Malady 于 9 月 5 日在一笔交易中出售了 667 股该公司的股票。这些股票以平均价格 80.86 美元出售，总交易额为 53,933.62 美元。出售后，该董事在公司中持有 22,667 股，价值约为 1,832,853.62 美元。这代表其持股减少了 2.86%。该交易的披露信息可以在此找到。在过去三个月中，内部人士已出售了价值 1,263,480 美元的 15,237 股公司股票。0.32% 的股票由公司内部人士持有。</p>
<h2>关于 DexCom</h2>
<p>(免费报告)</p>
<p>德康医疗公司是一家医疗设备公司，专注于在美国及国际市场设计、开发和商业化连续血糖监测（CGM）系统。该公司为糖尿病患者及医疗服务提供者提供其系统。其产品包括 Dexcom G6 和 Dexcom G7，集成的 CGM 系统用于糖尿病管理；Dexcom Share，远程监测系统；Dexcom Real-Time API，使授权的第三方软件开发者能够将实时 CGM 数据集成到他们的数字健康应用和设备中；以及 Dexcom ONE，旨在替代指尖血糖测试以进行糖尿病治疗决策。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们认为比德康医疗更好的股票</li>
<li>英国市场假期有哪些？如何投资和交易</li>
<li>接近阻力位的高飞股票：3 只值得关注的股票</li>
<li>什么是标准普尔 500 指数，它与其他指数有何不同</li>
<li>希捷科技引领标准普尔 500：其 120% 涨幅背后的原因是什么？</li>
<li>期权交易 - 理解行使价格</li>
<li>先锋集团的 VUG ETF：您投资组合的终极成长 ETF</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFhDTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFhDTQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在德康医疗吗？</h2>
<p>在您考虑德康医疗之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而德康医疗并不在名单上。</p>
<p>虽然德康医疗目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

德康医疗

抵押贷款支持证券 ETF - iShares

<p>MBB Public Markets I LLC 已经收购了 DexCom, Inc.（NASDAQ:DXCM）的新股份，购买了 4,154 股，价值约 284,000 美元。其他机构投资者也增加了对 DexCom 的持股。分析师对该股票给予了 “适度买入” 的共识评级，目标价格为 99.89 美元。DexCom 报告的每股收益为 0.48 美元，超出预期，上一季度的收入为 11.6 亿美元，同比增长 15.2%</p>

<p>MBB Public Markets I LLC acquired a new stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) during the first quarter, according to its most recent filing with the Securities &amp; Exchange Commission. The firm acquired 4,154 shares of the medical device company's stock, valued at approximately $284,000.</p>
<div class="lb-trans"><p>MBB Public Markets I LLC 在第一季度根据其最近向证券交易委员会提交的文件收购了 DexCom, Inc. (NASDAQ:DXCM - 免费报告) 的新股份。该公司收购了 4,154 股医疗设备公司的股票，价值约为 284,000 美元。</p>
</div><ul>
<li>DexCom Stock: Earnings Beat and New Market Access Drive Bull Case</li>
</ul>
<div class="lb-trans"><ul>
<li>DexCom 股票：盈利超预期和新市场准入推动看涨案例</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors have also recently modified their holdings of DXCM. Golden State Wealth Management LLC lifted its position in DexCom by 211.2% during the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after acquiring an additional 264 shares during the last quarter. Private Trust Co. NA lifted its position in DexCom by 99.4% during the first quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock valued at $46,000 after acquiring an additional 335 shares during the last quarter. Farther Finance Advisors LLC lifted its position in DexCom by 29.3% during the first quarter. Farther Finance Advisors LLC now owns 3,100 shares of the medical device company's stock valued at $209,000 after acquiring an additional 702 shares during the last quarter. Dynamic Advisor Solutions LLC lifted its position in DexCom by 34.2% during the first quarter. Dynamic Advisor Solutions LLC now owns 5,235 shares of the medical device company's stock valued at $357,000 after acquiring an additional 1,333 shares during the last quarter. Finally, Stonebridge Financial Group LLC lifted its position in DexCom by 944.5% during the first quarter. Stonebridge Financial Group LLC now owns 3,217 shares of the medical device company's stock valued at $220,000 after acquiring an additional 2,909 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他一些对冲基金和机构投资者最近也调整了对 DXCM 的持股。Golden State Wealth Management LLC 在第一季度将其在 DexCom 的持仓提高了 211.2%。Golden State Wealth Management LLC 目前拥有 389 股医疗设备公司的股票，价值 27,000 美元，此前在上个季度又收购了 264 股。Private Trust Co. NA 在第一季度将其在 DexCom 的持仓提高了 99.4%。Private Trust Co. NA 目前拥有 672 股医疗设备公司的股票，价值 46,000 美元，此前在上个季度又收购了 335 股。Farther Finance Advisors LLC 在第一季度将其在 DexCom 的持仓提高了 29.3%。Farther Finance Advisors LLC 目前拥有 3,100 股医疗设备公司的股票，价值 209,000 美元，此前在上个季度又收购了 702 股。Dynamic Advisor Solutions LLC 在第一季度将其在 DexCom 的持仓提高了 34.2%。Dynamic Advisor Solutions LLC 目前拥有 5,235 股医疗设备公司的股票，价值 357,000 美元，此前在上个季度又收购了 1,333 股。最后，Stonebridge Financial Group LLC 在第一季度将其在 DexCom 的持仓提高了 944.5%。Stonebridge Financial Group LLC 目前拥有 3,217 股医疗设备公司的股票，价值 220,000 美元，此前在上个季度又收购了 2,909 股。目前 97.75% 的股票由机构投资者持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>A number of equities research analysts recently commented on DXCM shares. Canaccord Genuity Group reissued a &#34;buy&#34; rating and set a $106.00 target price on shares of DexCom in a research report on Friday, August 1st. Argus initiated coverage on shares of DexCom in a report on Thursday, August 21st. They issued a &#34;buy&#34; rating and a $100.00 price target for the company. William Blair raised shares of DexCom to a &#34;strong-buy&#34; rating in a report on Thursday, July 31st. Mizuho raised their price target on shares of DexCom from $95.00 to $100.00 and gave the stock an &#34;outperform&#34; rating in a report on Wednesday, July 16th. Finally, Morgan Stanley raised their price target on shares of DexCom from $82.00 to $89.00 and gave the stock an &#34;equal weight&#34; rating in a report on Tuesday, July 15th. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $99.89.</p>
<div class="lb-trans"><p>一些股票研究分析师最近对 DXCM 股票发表了评论。Canaccord Genuity Group 在 8 月 1 日的研究报告中重申了 &#34;买入&#34; 评级，并设定了 106.00 美元的目标价。Argus 在 8 月 21 日的报告中开始覆盖 DexCom 股票。他们对该公司给予了 &#34;买入&#34; 评级和 100.00 美元的目标价。William Blair 在 7 月 31 日的报告中将 DexCom 股票评级提升至 &#34;强力买入&#34;。Mizuho 在 7 月 16 日的报告中将 DexCom 股票的目标价从 95.00 美元提高至 100.00 美元，并给予该股票 &#34;跑赢大盘&#34; 的评级。最后，摩根士丹利在 7 月 15 日的报告中将 DexCom 股票的目标价从 82.00 美元提高至 89.00 美元，并给予该股票 &#34;持平&#34; 的评级。三位分析师对该股票给予了强力买入评级，十四位给予了买入评级，五位给予了持有评级。根据 MarketBeat.com 的数据，该公司的平均评级为 &#34;适度买入&#34;，共识目标价为 99.89 美元。</p>
</div><ul>
<li>3 New ETFs Finding Early Traction With Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只新 ETF 正在吸引投资者的关注</li>
</ul>
</div><p><strong>Read Our Latest Research Report on DXCM</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 DXCM 的最新研究报告</strong></p>
</div><h2>DexCom Price Performance</h2>
<div class="lb-trans"><h2>DexCom 价格表现</h2>
</div><p>NASDAQ:DXCM opened at $76.00 on Friday. The firm has a market capitalization of $29.80 billion, a P/E ratio of 52.78, a PEG ratio of 1.59 and a beta of 1.48. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $93.25. The company's fifty day moving average price is $81.01 and its 200-day moving average price is $78.80. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35.</p>
<div class="lb-trans"><p>NASDAQ:DXCM 周五开盘价为 76.00 美元。该公司的市值为 298 亿美元，市盈率为 52.78，PEG 比率为 1.59，贝塔值为 1.48。DexCom, Inc. 的一年低点为 57.52 美元，一年高点为 93.25 美元。该公司的 50 日移动平均价格为 81.01 美元，200 日移动平均价格为 78.80 美元。该公司的债务与股本比率为 0.48，流动比率为 1.52，速动比率为 1.35。</p>
</div><ul>
<li>Top 3 Stocks to Watch: Options Traders Bet on Big Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>关注的三只股票：期权交易者押注大幅收益</li>
</ul>
</div><p>DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, topping analysts' consensus estimates of $0.45 by $0.03. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business's quarterly revenue was up 15.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.</p>
<div class="lb-trans"><p>DexCom (NASDAQ:DXCM - 获取免费报告) 最近于 7 月 30 日发布了季度财报。该医疗设备公司报告本季度每股收益为 0.48 美元，超出分析师共识预期的 0.45 美元，超出幅度为 0.03 美元。该公司本季度的收入为 11.6 亿美元，而分析师预期为 11.3 亿美元。DexCom 的净利润率为 13.29%，股本回报率为 30.41%。与去年同期相比，该公司的季度收入增长了 15.2%。在去年同期，该公司每股收益为 0.43 美元。DexCom 已设定其 2025 财年的每股收益指导。整体而言，股票研究分析师预计 DexCom, Inc. 今年将发布 2.03 的每股收益。</p>
</div><h2>Insider Transactions at DexCom</h2>
<div class="lb-trans"><h2>DexCom 的内部交易</h2>
</div><p>In other news, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction on Friday, August 15th. The shares were sold at an average price of $81.06, for a total value of $222,915.00. Following the sale, the director owned 51,121 shares in the company, valued at $4,143,868.26. This represents a 5.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through the SEC website. Also, Director Kyle Malady sold 667 shares of the firm's stock in a transaction on Friday, September 5th. The shares were sold at an average price of $80.86, for a total transaction of $53,933.62. Following the sale, the director owned 22,667 shares in the company, valued at approximately $1,832,853.62. This represents a 2.86% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 15,237 shares of company stock valued at $1,263,480. 0.32% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他消息中，董事 Mark G. Foletta 于 8 月 15 日在一笔交易中出售了 2,750 股该股票。这些股票以平均价格 81.06 美元出售，总价值为 222,915.00 美元。出售后，该董事在公司中持有 51,121 股，价值 4,143,868.26 美元。这代表其持股减少了 5.10%。该交易已在向证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站获取。此外，董事 Kyle Malady 于 9 月 5 日在一笔交易中出售了 667 股该公司的股票。这些股票以平均价格 80.86 美元出售，总交易额为 53,933.62 美元。出售后，该董事在公司中持有 22,667 股，价值约为 1,832,853.62 美元。这代表其持股减少了 2.86%。该交易的披露信息可以在此找到。在过去三个月中，内部人士已出售了价值 1,263,480 美元的 15,237 股公司股票。0.32% 的股票由公司内部人士持有。</p>
</div><h2>About DexCom</h2>
<div class="lb-trans"><h2>关于 DexCom</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.</p>
<div class="lb-trans"><p>德康医疗公司是一家医疗设备公司，专注于在美国及国际市场设计、开发和商业化连续血糖监测（CGM）系统。该公司为糖尿病患者及医疗服务提供者提供其系统。其产品包括 Dexcom G6 和 Dexcom G7，集成的 CGM 系统用于糖尿病管理；Dexcom Share，远程监测系统；Dexcom Real-Time API，使授权的第三方软件开发者能够将实时 CGM 数据集成到他们的数字健康应用和设备中；以及 Dexcom ONE，旨在替代指尖血糖测试以进行糖尿病治疗决策。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than DexCom</li>
<li>What Are the U.K. Market Holidays? How to Invest and Trade</li>
<li>High-Flyers Near Resistance: 3 Stocks to Watch for a Dip</li>
<li>What is the S&amp;P 500 and How It is Distinct from Other Indexes</li>
<li>Seagate Technology Leads S&amp;P 500: What’s Behind Its 120% Gain?</li>
<li>Options Trading - Understanding Strike Price</li>
<li>Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比德康医疗更好的股票</li>
<li>英国市场假期有哪些？如何投资和交易</li>
<li>接近阻力位的高飞股票：3 只值得关注的股票</li>
<li>什么是标准普尔 500 指数，它与其他指数有何不同</li>
<li>希捷科技引领标准普尔 500：其 120% 涨幅背后的原因是什么？</li>
<li>期权交易 - 理解行使价格</li>
<li>先锋集团的 VUG ETF：您投资组合的终极成长 ETF</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFhDTQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=DXCM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in DexCom Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在德康医疗吗？</h2>
</div><p>Before you consider DexCom, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑德康医疗之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DexCom wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而德康医疗并不在名单上。</p>
</div><p>While DexCom currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然德康医疗目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

MBB Public Markets I LLC 在德康医疗公司 $DXCM 中建立了头寸